Clinical Trial

Gastric Emptying With Metoclopramide in GLP-1 Agonist Patients Undergoing Elective Surgery

Study acronym: GEM-GLP1RA
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated August 6, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multicentre, investigator-blinded, randomised controlled trial evaluating whether the use of oral metoclopramide before surgery can reduce the amount of residual gastric content in patients who are taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss. These medications are known to slow down gastric emptying, which may increase the risk of pulmonary aspiration during anaesthesia. Patients will be randomly assigned to either receive metoclopramide 24 hours before surgery or continue with standard care. The primary outcome will be the presence or absence of residual gastric content on ultrasound before surgery. Secondary outcomes include nausea, vomiting, constipation, and any adverse effects of the medication.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-27.
Trial Details
NCT Number NCT07100691
Lead Sponsor Mater Misericordiae University Hospital
Conditions Pulmonary Aspiration During Anaesthetic Induction, Gastric Emptying Time, Preoperative Risk Assessment, Obesity (Disorder)
Enrollment 80 participants
Start Date 2025-08
Primary Completion 2026-05 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-08-06